$TXMD
TherapeuticsMD, Inc.

2023 Q4 Form 10-Q Financial Statement

#000119312523277143 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $502.0K -$53.00K
YoY Change -56.42% -100.25%
Cost Of Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Gross Profit $502.0K -$53.00K
YoY Change -96.18% -100.31%
Gross Profit Margin 100.0%
Selling, General & Admin $1.476M $1.590M
YoY Change -39.95% -95.68%
% of Gross Profit 294.02%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $632.0K $0.00
YoY Change -131.79% -100.0%
% of Gross Profit 125.9%
Operating Expenses $2.113M $1.720M
YoY Change -103.34% -95.46%
Operating Profit -$1.611M -$1.773M
YoY Change -102.11% -91.45%
Interest Expense $115.0K $20.00K
YoY Change -99.59%
% of Operating Profit
Other Income/Expense, Net -$88.00K $339.0K
YoY Change -99.91% -104.0%
Pretax Income -$1.584M -$1.434M
YoY Change -95.27% -95.09%
Income Tax -$43.00K
% Of Pretax Income
Net Earnings -$883.0K -$3.378M
YoY Change -101.14% -88.34%
Net Earnings / Revenue -175.9%
Basic Earnings Per Share -$0.32
Diluted Earnings Per Share -$0.07 -$0.32
COMMON SHARES
Basic Shares Outstanding 10.58M 10.58M
Diluted Shares Outstanding 10.70M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.327M $10.20M
YoY Change -88.63% -62.33%
Cash & Equivalents $4.327M $49.32M
Short-Term Investments
Other Short-Term Assets $4.379M $4.200M
YoY Change -74.66% -80.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.80M $17.44M
YoY Change -78.69% -80.06%
LONG-TERM ASSETS
Property, Plant & Equipment $19.00K
YoY Change -96.55%
Goodwill
YoY Change
Intangibles $6.098M $6.657M
YoY Change -12.17% -82.42%
Long-Term Investments
YoY Change
Other Assets $58.00K $254.0K
YoY Change -77.08% 0.4%
Total Long-Term Assets $31.51M $33.05M
YoY Change -10.24% -28.81%
TOTAL ASSETS
Total Short-Term Assets $11.80M $17.44M
Total Long-Term Assets $31.51M $33.05M
Total Assets $43.31M $50.49M
YoY Change -52.12% -62.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.00K $696.0K
YoY Change -98.75% -94.8%
Accrued Expenses $2.724M $3.700M
YoY Change -84.2% -90.45%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.854M $14.51M
YoY Change -85.37% -91.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $636.0K $1.189M
YoY Change -42.55% 114.62%
Total Long-Term Liabilities $636.0K $1.189M
YoY Change -42.55% 114.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.854M $14.51M
Total Long-Term Liabilities $636.0K $1.189M
Total Liabilities $14.02M $22.44M
YoY Change -74.65% -87.68%
SHAREHOLDERS EQUITY
Retained Earnings -$949.6M -$948.8M
YoY Change 1.09% -6.72%
Common Stock $11.00K $976.8M
YoY Change -100.0% 0.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $29.29M $28.05M
YoY Change
Total Liabilities & Shareholders Equity $43.31M $50.49M
YoY Change -52.12% -62.29%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$883.0K -$3.378M
YoY Change -101.14% -88.34%
Depreciation, Depletion And Amortization $632.0K $0.00
YoY Change -131.79% -100.0%
Cash From Operating Activities -$7.841M -$2.450M
YoY Change -113.12% -87.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.001M -1.110M
YoY Change -101.54% -105.63%
NET CHANGE
Cash From Operating Activities -7.841M -2.450M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 2.001M -1.110M
Net Change In Cash -5.840M -3.560M
YoY Change -153.15% -558.17%
FREE CASH FLOW
Cash From Operating Activities -$7.841M -$2.450M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$7.841M -$2.450M
YoY Change -113.13% -87.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
THERAPEUTICSMD, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0000025743
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-00100
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0233535
dei Entity Address Address Line1
EntityAddressAddressLine1
951 Yamato Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 220
dei Entity Address City Or Town
EntityAddressCityOrTown
Boca Raton
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33431
dei City Area Code
CityAreaCode
561
dei Local Phone Number
LocalPhoneNumber
961-1900
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
TXMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10575240
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.02
CY2023Q3 us-gaap Cash
Cash
10166000
CY2022Q4 us-gaap Cash
Cash
38067000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
11250000
CY2023Q3 txmd Royalty Receivable Current
RoyaltyReceivableCurrent
2705000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4570000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6034000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
17441000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
55351000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6657000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6943000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7055000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7580000
CY2023Q3 txmd Royalty Receivable Long Term
RoyaltyReceivableLongTerm
19067000
CY2022Q4 txmd Royalty Receivable Long Term
RoyaltyReceivableLongTerm
20253000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
254000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
253000
CY2023Q3 us-gaap Assets
Assets
50493000
CY2022Q4 us-gaap Assets
Assets
90458000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
696000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2162000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
6928000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18846000
CY2023Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
6888000
CY2022Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
25831000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14512000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46839000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6740000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7369000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1189000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1107000
CY2023Q3 us-gaap Liabilities
Liabilities
22441000
CY2022Q4 us-gaap Liabilities
Liabilities
55315000
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
32000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10575000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10575000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9498000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9498000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
976799000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
974497000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-948758000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-939363000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28052000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35143000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50493000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90458000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
-53000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
354000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
800000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1397000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
354000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1397000
CY2023Q3 us-gaap Gross Profit
GrossProfit
-53000
CY2022Q3 us-gaap Gross Profit
GrossProfit
0
us-gaap Gross Profit
GrossProfit
800000
us-gaap Gross Profit
GrossProfit
0
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1590000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14246000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7427000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46367000
CY2023Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
130000
CY2022Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
273000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
285000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
884000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1720000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
14519000
us-gaap Operating Expenses
OperatingExpenses
7712000
us-gaap Operating Expenses
OperatingExpenses
47251000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1773000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14519000
us-gaap Operating Income Loss
OperatingIncomeLoss
-6912000
us-gaap Operating Income Loss
OperatingIncomeLoss
-47251000
CY2023Q3 us-gaap Interest Expense
InterestExpense
20000
CY2022Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
115000
us-gaap Interest Expense
InterestExpense
0
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
359000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-112000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
869000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-128000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
339000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-112000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
754000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-128000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1434000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14631000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6158000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47379000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1944000
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-14334000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-3237000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
81674000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3378000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28965000
us-gaap Net Income Loss
NetIncomeLoss
-9395000
us-gaap Net Income Loss
NetIncomeLoss
34295000
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.13
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.13
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.58
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.58
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.6
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.6
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-5.34
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-5.34
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.18
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.18
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.55
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.55
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.32
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.32
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
9.2
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
9.2
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.13
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.92
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.86
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.86
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10701000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9261000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10241000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8877000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10701000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9261000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10241000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8877000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3378000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28965000
us-gaap Net Income Loss
NetIncomeLoss
-9395000
us-gaap Net Income Loss
NetIncomeLoss
34295000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3378000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28965000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9395000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
34295000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
35143000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
1000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
483000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3603000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
32024000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1150000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
437000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-2414000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
31197000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
233000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3378000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28052000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-93621000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2062000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-49021000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-140580000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
14000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2219000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
112281000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-26066000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2454000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4306000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28965000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-48271000
us-gaap Net Income Loss
NetIncomeLoss
-9395000
us-gaap Net Income Loss
NetIncomeLoss
34295000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
-3237000
us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
81674000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6158000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-47379000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
285000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
884000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
59000
us-gaap Share Based Compensation
ShareBasedCompensation
1155000
us-gaap Share Based Compensation
ShareBasedCompensation
8587000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
525000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-25000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1185000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1241000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-394000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1466000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1290000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-11918000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
18337000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-629000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
82000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-385000
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-11963000
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
26502000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18121000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20877000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
260000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-281000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1149000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2454000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000
us-gaap Repayments Of Debt
RepaymentsOfDebt
125000000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
729000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1149000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-123261000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-22179000
us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
117573000
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
0
us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
54000
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
0
us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
0
us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
-22179000
us-gaap Net Cash Provided By Used In Discontinued Operations
NetCashProvidedByUsedInDiscontinuedOperations
117627000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-39151000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-26792000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49317000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65122000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
0
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10166000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38330000
us-gaap Interest Paid Net
InterestPaidNet
0
txmd Non Cash Payment Of Interest And Increase In Debt
NonCashPaymentOfInterestAndIncreaseInDebt
2452000
txmd Non Cash Payment Of Financing Fees And Increase In Debt
NonCashPaymentOfFinancingFeesAndIncreaseInDebt
16980000
txmd Issue Of Warrants Lenders Related To Debt Financing Fees
IssueOfWarrantsLendersRelatedToDebtFinancingFees
1983000
CY2022Q4 txmd Purchase Of Transferred Assets And Grant Of Licenses Cash Payment
PurchaseOfTransferredAssetsAndGrantOfLicensesCashPayment
140000000
CY2022Q4 txmd Payments To Acquire Net Working Capital
PaymentsToAcquireNetWorkingCapital
12100000
CY2022Q4 us-gaap Proceeds From Royalties Received
ProceedsFromRoyaltiesReceived
1000000
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
outstanding Common Stock were split at a ratio of 50-for-1
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
110000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
439000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
12000000
CY2023Q2 txmd Revised Common Stock Shares Authorized
RevisedCommonStockSharesAuthorized
32000000
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Estimates and assumptions </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of our condensed consolidated financial statements in conformity with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. We evaluate our estimates and assumptions based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions. </div></div></div>
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
632000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1167000
CY2023Q3 us-gaap Prepaid Rent
PrepaidRent
429000
CY2023Q3 us-gaap Acquisition Costs Cumulative
AcquisitionCostsCumulative
2334000
CY2022Q4 us-gaap Acquisition Costs Cumulative
AcquisitionCostsCumulative
2334000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1175000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2533000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4570000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6034000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2522000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2523000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2503000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2445000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78000
CY2023Q3 us-gaap Depreciation
Depreciation
0
CY2022Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
0
us-gaap Depreciation
Depreciation
400000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8160000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1824000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6336000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
8220000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1598000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6622000
CY2023Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8481000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1824000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6657000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
8541000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1598000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6943000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
438000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
438000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
438000
CY2023Q3 txmd Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
2537000
CY2023Q3 txmd Finite Lived Intangible Assets Amortization Expense Net
FiniteLivedIntangibleAssetsAmortizationExpenseNet
4400000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
332000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8748000
CY2023Q3 txmd Accrued Contract Termination Costs
AccruedContractTerminationCosts
1632000
CY2022Q4 txmd Accrued Contract Termination Costs
AccruedContractTerminationCosts
4700000
CY2022Q4 txmd Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
978000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
273000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
415000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1464000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1390000
CY2023Q3 txmd Accrued Prepaid Royalty
AccruedPrepaidRoyalty
0
CY2022Q4 txmd Accrued Prepaid Royalty
AccruedPrepaidRoyalty
1011000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3227000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1604000
CY2023Q3 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6928000
CY2022Q4 txmd Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
18846000
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.13
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-1.58
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.6
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-5.34
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.13
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-1.58
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.6
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-5.34
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
172000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
228.28
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y7M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
170000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
229.43
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
92000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
206.54
txmd Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Options Expired Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOptionsExpiredNumber
-90000
txmd Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Options Expired Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOptionsExpiredWeightedAverageExercisePrice
206.54
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
80000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
253.31
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y2M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
80000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
253.31
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y2M12D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
200000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4300000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8500000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
400000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y7M6D
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.18
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-1.55
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.32
txmd Effective Income Tax Rate Discontinued Operations
EffectiveIncomeTaxRateDiscontinuedOperations
0
txmd Effective Income Tax Rate Discontinued Operations
EffectiveIncomeTaxRateDiscontinuedOperations
0
CY2023Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-1434000
CY2022Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-14631000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-6158000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-47379000
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-1944000
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-14334000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-3237000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
81674000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3378000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-28965000
us-gaap Net Income Loss
NetIncomeLoss
-9395000
us-gaap Net Income Loss
NetIncomeLoss
34295000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10701000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9261000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10241000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8877000
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10701000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9261000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10241000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8877000
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
9.2
CY2023Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.18
CY2022Q3 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-1.55
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.32
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
9.2
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
277000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1009000

Files In Submission

Name View Source Status
d569965d10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
0001193125-23-277143-index-headers.html Edgar Link pending
0001193125-23-277143-index.html Edgar Link pending
0001193125-23-277143.txt Edgar Link pending
0001193125-23-277143-xbrl.zip Edgar Link pending
d569965d10q.htm Edgar Link pending
d569965dex101.htm Edgar Link pending
d569965dex311.htm Edgar Link pending
d569965dex312.htm Edgar Link pending
d569965dex321.htm Edgar Link pending
d569965dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
txmd-20230930.xsd Edgar Link pending
txmd-20230930_cal.xml Edgar Link unprocessable
txmd-20230930_def.xml Edgar Link unprocessable
txmd-20230930_pre.xml Edgar Link unprocessable
txmd-20230930_lab.xml Edgar Link unprocessable